Transgene S.A. (USD) Transgene S.A. is a biotechnology company dedicated to the creation and advancement of therapeutic vaccines and oncolytic viruses. Its core mission is to develop innovative treatments for both cancer and various infectious diseases. The company's drug development pipeline includes several promising candidates: TG4050, a therapeutic vaccine, is currently in early-stage Phase I clinical trials for its potential use against ovarian cancer and certain types of HPV-negative head and neck cancers. TG4001, another therapeutic vaccine, has progressed to Phase II clinical trials, where it is being evaluated for the treatment of HPV-positive cancers. TG6002, an oncolytic virus, is undergoing Phase I/IIa clinical development, targeting a diverse range of solid tumors, specifically gastrointestinal adenocarcinomas affecting the stomach, pancreas, and colon. BT-001, also an oncolytic virus, is in Phase I/II clinical trials for various solid tumor indications. Beyond these, Transgene's portfolio also features TG1050, a therapeutic vaccine aimed at chronic hepatitis B, and Pexa-Vec, an oncolytic virus designed to address solid tumors. To bolster its research and development efforts, Transgene has established key strategic partnerships with prominent pharmaceutical companies including AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation. Furthermore, it holds licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva, and maintains additional collaborations with Sanofi, BioInvent, and Randox. Founded in 1979, Transgene S.A. is based in Illkirch-Graffenstaden, France, and operates as a subsidiary of TSGH SAS.

Transgene S.A. (USD) Passive

400, Boulevard Gonthier d’Andernach, Illkirch-Graffenstaden, FR, 67405

Stock Price USD

Price Change

Last Dividend USD

TRGNF's stock peer is CMVLF (Cellectis S.A.)

TRGNF's stock peer is GNFTF (Genfit S.a.)

TRGNF's stock peer is HNSBF (Hansa Biopharma AB)

TRGNF's stock peer is MAYNF (Mayne Pharma Group Limited)

TRGNF's stock peer is ORYZF (Oryzon Genomics S.A.)

TRGNF's stock peer is PBBIF (Probi AB (publ))

TRGNF's stock peer is PRRUF (Immutep Ltd)

TRGNF's stock peer is SLNCF (Silence Therapeutics plc)

TRGNF's stock peer is SPHDF (Santhera Pharmaceuticals Holding AG)

Healthcare Biotechnology

Transgene S.A. is a biotechnology company dedicated to the creation and advancement of therapeutic vaccines and oncolytic viruses. Its core mission is to develop innovative treatments for both cancer and various infectious diseases. The company's drug development pipeline includes several promising candidates: TG4050, a therapeutic vaccine, is currently in early-stage Phase I clinical trials for its potential use against ovarian cancer and certain types of HPV-negative head and neck cancers. TG4001, another therapeutic vaccine, has progressed to Phase II clinical trials, where it is being evaluated for the treatment of HPV-positive cancers. TG6002, an oncolytic virus, is undergoing Phase I/IIa clinical development, targeting a diverse range of solid tumors, specifically gastrointestinal adenocarcinomas affecting the stomach, pancreas, and colon. BT-001, also an oncolytic virus, is in Phase I/II clinical trials for various solid tumor indications. Beyond these, Transgene's portfolio also features TG1050, a therapeutic vaccine aimed at chronic hepatitis B, and Pexa-Vec, an oncolytic virus designed to address solid tumors. To bolster its research and development efforts, Transgene has established key strategic partnerships with prominent pharmaceutical companies including AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation. Furthermore, it holds licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva, and maintains additional collaborations with Sanofi, BioInvent, and Randox. Founded in 1979, Transgene S.A. is based in Illkirch-Graffenstaden, France, and operates as a subsidiary of TSGH SAS.

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
Dividend Data Not Exist

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions